Effect of a fermented dairy beverage on treatment-related toxicity and inflammation in locally advanced cervical cancer patients, a randomized placebo-controlled pilot study.
Preprint
- 18 July 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose. This study aimed to analyze the effect of a probiotic-rich fermented dairy beverage, compared to a placebo, on gastrointestinal toxicity, inflammatory response, chronic toxicity, and quality of life, in locally advanced cervical cancer (LACC) patients. Methods. A randomized, double blind, placebo-controlled pilot study assigned LACC patients to the probiotic group (n=21) or the placebo group (n=21). Intervention with probiotic or placebo beverage began 2 weeks before treatment through 90 days after treatment. The frequency and severity of toxicity symptoms, nutritional parameters, serum cytokines, fecal calprotectin, proctopathy, and quality of life were evaluated throughout treatment. Results.Lower frequency and severity of vomit were observed in the probiotic group compared to placebo (15% vs 40%, p=0.03). No differences were observed in the frequency of symptoms among groups, including diarrhea. A trend was observed toward lower levels of inflammatory cytokines in the probiotic group. No significant differences were observed in the development of proctopathy. Conclusion.This study demonstrated the fermented dairy beverage’s beneficial effect on reducing the frequency and severity of vomit and a tendency to lower inflammation. Still, it did not provide benefits regarding other treatment-related toxicities, probably due to the small sample size. Trial Registration Number NCT05736315, retrospectively registered on February 16, 2023.Keywords
All Related Versions
This publication has 56 references indexed in Scilit:
- Gastrointestinal cancers: Influence of gut microbiota, probiotics and prebioticsCancer Letters, 2014
- Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: a cohort studyBMC Cancer, 2010
- Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patientsRadiation Oncology, 2010
- Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapyAlimentary Pharmacology & Therapeutics, 2009
- Effects of Probiotic Lactobacillus Casei DN-114 001 in Prevention of Radiation-Induced Diarrhea: Results From Multicenter, Randomized, Placebo-Controlled Nutritional TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancerGynecologic Oncology, 2006
- Is concurrent chemotherapy and radiotherapy the new standard of care for locally advanced cervical cancer?International Journal of Gynecological Cancer, 2001
- ChemoradiotherapyDrugs, 2000
- The Consequences of Diarrhea Occurring During Chemotherapy for Colorectal Cancer: A Retrospective StudyThe Oncologist, 2000
- Tumour necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinomaEuropean Journal of Cancer, 1994